Live
FierceBiotechUCB inks $2B Candid buyout to join Gilead in autoimmune fieldIlluminaIllumina Partners with Florida State University Lab for Rare Disease Genome Sequencing - Clinical Lab ProductsBioPharma DiveUCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseasesBioPharma DiveWhat is your AI drug repurposing strategy missing?FierceBiotech‘Real momentum’ or ‘completely absurd’? How Trump’s support has shaken up psychedelicsCytiva (Google News)Rockwell Automation and Cytiva join hands to accelerate digital transformation for biopharma companies - BioSpectrum AsiaCytiva (Google News)Rockwell Automation and Cytiva Introduce Figurate SCADA: Addressing Digital Fragmentation in Biopharma Manufacturing - ARCweb.comLonza NewsAntibody Drug Conjugates Contract Market: North America Leads; - openPR.comFierceBiotechScaling theranostics through access, safety and trustEndpoints NewsUCB bets $2 billion on Candid's T cell engager ambitionsIlluminaWilkins Investment Counsel Inc. Trims Stake in Illumina, Inc. $ILMN - MarketBeatSamsung Biologics(LEAD) Samsung Biologics labor union set to resume talks with management on Monday - Yonhap News Agency
10x Genomics Blog Mar 20, 2026

Cathie Wood’s ARK adds 10x Genomics stock, trims Arcturus By Investing.com - Investing.com Australia

Cathie Wood’s ARK adds 10x Genomics stock, trims Arcturus By Investing.com - Investing.com Australia

Original
Body unavailable. Use the original source.